Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Greek Parliament to Vote on Prosecutions in Novartis Bribery Case

share with twitter share with LinkedIn share with facebook
05/18/2018 | 08:17am EDT

By Nektaria Stamouli and Donato Paolo Mancini

ATHENS--Greece's Parliament is set to vote later on Friday on whether or not to request the prosecution of high-profile politicians allegedly involved in a bribery case with Swiss pharmaceutical giant Novartis.

Parliament is expected to conclude it cannot investigate the allegations and that the file should be returned to judicial authorities.

In Greece, Novartis is accused of bribing high-profile politicians, public officials and thousands of doctors to boost its sales in order to build a dominant position in the country's health-care market and secure artificially high prices for its products. The case is under examination by the Greek and U.S. authorities.

Greek anticorruption prosecutors alleged that 4,500 doctors and 10 high profile politicians, including two former prime ministers, a former head of the central bank and a European commissioner are involved in the Novartis price-fixing scandal.

The activity occurred between 2006 and 2015 and involved 4,500 doctors as well, covering the period during which Greece was bailed out and was living under tight scrutiny by its international creditors. The country has slashed health-care spending to fix its finances.

All politicians denied wrongdoing. Opposition parties accused the government of stoking the scandal for political gain. Novartis has said that it has been cooperating with Greek authorities and that it will take "decisive" action if any wrongdoing is found.

The case was referred to parliament by prosecutors in February because, under Greek law, this is the only institution that can investigate politicians and lift their immunity if it finds evidence of criminal activity. Prosecutors referred their investigation to parliament this month.

Novartis is under pressure after drawing the attention of Swiss prosecutors after disclosing last week that it had paid a total of $1.2 million to Essential Consultants LLC, a company owned by Michael Cohen. Mr. Cohen is U.S. President Donald Trump's personal attorney.

Novartis said the payments were for what it called advice on "health-care policy matters."

Novartis's chief executive Vasant Narasimhan called the move a mistake. The company said payments could only cease in February 2018 even if the company had been determined Mr. Cohen was unable to effectively offer advice on health-care policy, and that Mr. Narasimhan was not involved in the deal with Mr. Cohen. Mr. Cohen declined to comment.

In the wake of the disclosures, Novartis's top lawyer, Felix Ehrat, said he would leave the company. Mr. Narasimhan said Wednesday at an investor meeting in Basel that changes in top management would be made, and that a new professional-practices policy would be in place so employees could "ask themselves the key questions before making a decision."

Swiss prosecutors said earlier this week they were in contact with one another over the disclosures, but declined to say whether charges were being considered.

Read more about Novartis's connection to Michael Cohen at https://on.wsj.com/2k61xoQ (WSJ) or https://bit.ly/2IN3Bjl (NewsPlus).

Write to Nektaria Stamouli at nektaria.stamouli@wsj.com and to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG -0.01% 75.49 Delayed Quote.-17.85%
SWISS RE LTD 1.85% 71.5 Delayed Quote.-35.42%
share with twitter share with LinkedIn share with facebook
Latest news on NOVARTIS AG
08/07Roche-PTC Therapeutics' oral spinal muscular atrophy drug wins FDA approval
08/07U.S. FDA approves Roche, PTC Therapeutics' spinal muscular atrophy drug
08/07CATALENT : Gene Therapy Facility Receives FDA Approval as an Additional Manufact..
08/06NOVARTIS : receives EC approval for new Xolair® indication to treat severe chron..
08/03NOVARTIS : Kymriah meets endpoint in follicular lymphoma trial
08/03NOVARTIS : gets European approval for psoriasis drug Cosentyx
07/31China to add 56 drugs to price-slashing bulk-buy programme
07/30NOVARTIS : receives Piqray approval in Europe the first and only targeted medici..
07/29China to add 56 drugs to price-slashing bulk-buy programme
07/29NOVARTIS : receives Piqray® approval in Europe – the first and only target..
More news
Financials (USD)
Sales 2020 49 512 M - -
Net income 2020 8 799 M - -
Net Debt 2020 20 241 M - -
P/E ratio 2020 20,2x
Yield 2020 3,80%
Capitalization 182 B 182 B -
EV / Sales 2020 4,09x
EV / Sales 2021 3,72x
Nbr of Employees 110 000
Free-Float 84,4%
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 104,08 $
Last Close Price 82,71 $
Spread / Highest target 56,7%
Spread / Average Target 25,8%
Spread / Lowest Target -1,52%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-17.85%182 240
JOHNSON & JOHNSON1.87%391 238
ROCHE HOLDING AG0.06%294 334
PFIZER, INC.-1.86%213 662
MERCK & CO., INC.-10.92%204 919
ABBVIE INC.4.95%163 988